InsidersTradesSigma
Follow the Tvardi Therapeutics, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €16.6m. The latest transaction was disclosed on 5 August 2025 (J). Among the most active insiders: HALL WALLACE L JR. All data is free.
Analysts rate Tvardi Therapeutics, Inc. Buy (bullish), based on 8 analysts. Average price target: US$8.50.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
Tvardi Therapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de tratamientos innovadores para enfermedades graves. Se especializa en el descubrimiento y la comercialización de terapias dirigidas.